By Francesco Guarascio, Khanh Vu and Mikhail Flores
HANOI/MANILA, Dec 6 (Reuters) – The World Organisation for Animal Health (WOAH) is warning that more testing of African swine fever vaccines is needed, triggered by Vietnam’s plans to export doses in coming months to fight a disease that regularly ravages pig farms worldwide.
In a world first, Vietnam authorised in July two attenuated live-virus vaccines against the disease, which is not deadly to humans but is extremely infectious among pigs and has caused repeated disruptions to the global pork market, which data provider Research and Markets said was worth about $250 billion in 2022.
WOAH says AVAC Vietnam JSC, the producer of one of the two vaccines, has not shared sufficient data with international researchers and bodies.
Gregorio Torres, head of the science department at WOAH, urged countries interested in using AVAC’s vaccines to conduct their own trials before approving it.
In October, as AVAC was about to announce deals with importers of its vaccine in the Philippines, Indonesia, Malaysia, India and Myanmar, WOAH warned of risks “from use of sub-standard vaccines”.
Torres said that Vietnam’s announcements led to the warning, but that it was not linked to concerns about specific vaccines.
AVAC says that its vaccine is not dangerous and that widespread use will demonstrate it.
“We have proven our product is safe and effective and we need some time to prove that to all, including those showing concern,” Nguyen Van Diep, AVAC’s chief operating officer, told Reuters.
He said the company had shared data. Nguyen Van Long, head of Vietnam’s Animal Health Department, said on Wednesday data on trials had been discussed in international conferences and meetings.
Diep said that the vaccine had been safely used in farms in 17 provinces in Vietnam since its approval and that sales were increasing.
Scientists at the U.S. Department of Agriculture (USDA) discovered the AVAC vaccine, which was then developed in Vietnam because the virus is not present in the United States. The agency did not have access to Vietnam’s trials data, a USDA spokesperson told Reuters.
“If somebody puts in the market a vaccine which is suboptimal, it will impact everybody,” Torres said, noting that it is harder to assess vaccines in countries with ongoing epidemics, such as Vietnam, because pigs could be infected by the attenuated virus in the vaccine alongside the wild virus.
Countries are eager for vaccines against African swine fever (ASF), which is incurable and has a high fatality rate, resulting in heavy losses for farms that become infected.
China has also developed several vaccines but none has gotten commercial approval.
AVAC is producing between 2.5 and 5 million doses a month and was planning to export 5 million, pending approval from the countries where the company signed commercial deals, Diep said, noting that a green light from the Philippines might come early next year.
TRADE SANCTIONS?
Torres said the agency was discussing a new global standard for evaluating ASF vaccines, with possible approval coming in May at the WOAH general assembly. The intergovernmental organisation, based in Paris, has 183 member states.
The standard would not be compulsory, as national regulators decide on approvals, but it could lead to trade restrictions against pork-exporting countries that vaccinate pigs with sub-standard shots.
The AVAC vaccine was trialled in the Philippines with 300,000 doses. The Food and Drug Administration of the Philippines, which is in charge of the vaccine approval, did not reply to requests for comment.
Philippines Agriculture Undersecretary Deogracias Victor Savellano told Reuters his country had not approved or purchased the vaccine yet, noting the regulator’s authorisation was critical to food security, as the country faces a national emergency caused by the spread of ASF.
Regulators from India, Indonesia, Myanmar and Malaysia did not respond to requests for comment.
The second approved ASF vaccine, produced by Vietnam’s Navetco Central Veterinary Medicine (VET.HNO) from a USDA platform, had shared positive trial data and is being tested in the Dominican Republic, the USDA said.
Navetco did not reply to a request for comment.
(Reporting by Francesco Guarascio @fraguarascio and Khanh Vu; additional reporting by Mai Nguyen in Hanoi, Mikhail Flores and Karen Lema in Manila, Rishika Sadam in Hyderabad, Dewi Kurniawati in Jakarta, Thu Thu Aung, and Rozanna Latiff in Kuala Lumpur; editing by Gerry Doyle and Mark Potter)
Our Privacy Commitment
TV5 Network Inc. values and respects your privacy. We are committed to safeguarding your personal data in compliance with Republic Act No. 10173 or the Data Privacy Act of 2012 and its implementing rules and regulations.
We have developed a Privacy Policy that adopts and observes appropriate standards for personal data protection. While our Privacy Policy sets out the general principles governing the collection, use, and disclosure of our users’ personal information, our Privacy Commitment seeks to inform you more about TV5’s privacy practices.
Why do we collect your personal information (as applicable)?
We may collect and maintain basic information about you as site user of TV5 sites for the following purposes:
Where do we get your personal information?
There are several ways we collect your personal information.
Information that you personally provided.
Most of the personal information we have are those that you have provided us when you:
Information we collect during your engagement with us
We also collect information as you use our products and services, like:
Information we collect from other sources
Other means of collection of information may be through:
When do we disclose personal information?
There may be instances when we are required to share the information you provided us. In such cases, we ensure that your personal information will be disclosed on a confidential manner, through secure channels and in compliance with the Data Privacy Act and other privacy laws.
We will never share, rent, or sell your personal information to third parties outside of TV5 except in special cases where you have given consent, and in cases described in our privacy policy.
In some instances, we may be required to disclose your personal information to our agents, subsidiaries, affiliates, business partners and other third-party agencies and service providers as part of our regular business operations and for the provision of our programs and services. This means we might share your information with our service providers, contractors, and professional advisers who help us provide our services.
How we protect your personal information
The integrity, confidentiality, and security of your information is important to us. We have implemented technical, organizational, and physical security measures that are designed to protect your information from unauthorized or fraudulent access, alteration, disclosure, misuse, and other unlawful activities.
We also put in effect the following safeguards:
TV5 will not collect, use, or disclose your personal information for any purpose other than the purpose that you may have given your consent for.
What are your choices?
We make sure that we have your consent to continue to collect, use, and disclose your personal information for the purposes that we have identified. We want you to know that you may object or withdraw your consent and/or edit your consent preferences at any time.
If you wish to have access to the personal information in our custody or if you think that the personal information you provided is incomplete, or otherwise inaccurate, you may get in touch with our Data Protection Officer through the contact details provided below. In some instances, we may request for supporting documents or proof before we effect requested changes.
Data Protection Officer
TV5 Network Inc.
Reliance corner Sheridan Streets
Mandaluyong City
tv5dataprivacy@tv5.com.ph
What happens when there are changes in our Policy?
From time to time, we may update our privacy policy and practices to comply with changes in applicable laws and regulatory requirements, adapt to new technologies and protocols, and align with the best practices of the industry.
You will be provided notices if the changes are significant and, if we are required by law, we will obtain your updated consent.